Pfizer Seeks Approval for Oral COVID-19 Antiviral Paxlovid
Paxlovid consists of nirmatrelvir and low-dose ritonavir.
COVID19
COVID-19 and Alcohol: A Pandemic Collides With a Public Health Crisis
Amid the global COVID-19 pandemic that overwhelmed hospitals, upended the economy, and sent much of the world into lockdown, researchers tracked a concerning uptick in alcohol use.
The Workweek Revolution: A Solution to the Health Care Exodus
The author describes the evolution of the workweek and how shortening the expected hours for full-time work without a decrease in compensation may increase the well-being of health care providers while not decreasing current productivity.
Shift Toward a Hyperdigitalized Lifestyle and Self-Isolation Can Lead to Dissociative Disorders
In an international online study participants completed a questionnaire to identify experiences of depersonalization and vividness of positive or negative emotions before and during COVID-19.
Pfizer-BioNTech Omicron-Adapted COVID-19 Vaccine Candidates Elicit Strong Immune Response
The trial evaluated booster doses of the Omicron-adapted vaccine candidates.
Positive Outcomes From an Infectious Disease Crisis
No crisis should go unexploited for its potential to improve health care delivery.
A COVID Silver Lining: Improved Well-Being Due to Connection With Nature
Using a shortened Nature Relatedness Scale, the Short Warwick-Edinburgh Mental Well-Being Scale (SWEMWBS), and sociodemographic information, the researchers surveyed 386 individuals aged 18 to 65 about their feelings of connection to nature and mental well-being.
FDA Authorizes COVID-19 Vaccines for Children as Young as 6 Months
The FDA evaluation included an analysis of safety, effectiveness and manufacturing data of these vaccines.
FDA Panel in Favor of COVID-19 Vaccines for Kids as Young as 6 Months
According to the CDC, as of June 7, 2022, there have been over 13.1 million cases of COVID-19 among children and adolescents 0 to 17 years of age.
Mixed Results for Paxlovid in Standard Risk Patients With COVID-19
The study evaluated Paxlovid in both vaccinated and unvaccinated patients with COVID-19 at standard risk for progressing to severe disease.
- Loading...
Loading...
Loading... 
Loading...